U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. Public Calendar - Meetings With FDA Officials
  5. Public Calendar: November 21-27, 2021
  1. Public Calendar - Meetings With FDA Officials

Public Calendar: November 21-27, 2021

This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.

Official Name: Janet Woodcock, M.D., Acting Commissioner

Event Date: 11/22/2021
Location: Virtual
Subject: User Fees
FDA Participant/Group: JULIA TIERNEY;
Non FDA Participant/Group: Cartier Esham, Khushboo Sharma, Michelle McMurray-Heath (Biotechnology Innovation Organization);

Event Date: 11/23/2021
Location: Virtual
Subject: User Fees
FDA Participant/Group: JULIA TIERNEY; KIMBERLY RAWLINGS;
Non FDA Participant/Group: Sharon Olmstead, Vas Narasimhan (Novartis);

Event Date: 11/23/2021
Location: Virtual
Subject: Biopharma Congress: Making Tough Decisions at FDA and What's Next for Janet Woodcock
FDA Participant/Group: N/A
Non FDA Participant/Group: Government, industry, media, and other registered guests

Event Date: 11/23/2021
Location: Virtual
Subject: User Fees
FDA Participant/Group: JULIA TIERNEY; KIMBERLY RAWLINGS;
Non FDA Participant/Group: Robert Bradway (Amgen);

Official Name: Andi Lipstein Fristedt, Deputy Commissioner for Policy, Legislation, and International Affair

No Significant Event

Official Name: Jim Sigg, Deputy Commissioner for Operations

No Significant Event

Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response

No Significant Event

Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy

No Significant Event

Official Name: Judy McMeekin, Associate Commissioner for Regulatory Affairs

No Significant Event

Official Name: Erica Jefferson, Associate Commissioner for External Affairs

No Significant Event

Official Name: Jacqueline O'Shaughnessy, Acting Chief Scientist

No Significant Event

Official Name: Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research

Event Date: 11/23/2021
Location: Virtual
Subject: Clozapine Risk Evaluation and Mitigation Strategies (REMS)
FDA Participant/Group: N/A
Non FDA Participant/Group: Representatives of the Clozapine Product Manufacturer Group (CPMG)

Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research

No Significant Event

Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health

No Significant Event

Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition

No Significant Event

Official Name: Mitchell R. Zeller, J.D., Director, Center for Tobacco Products

No Significant Event

Official Name: Steven Solomon, Director, Center for Veterinary Medicine

No Significant Event

Official Name: William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research

No Significant Event

Official Name: Mark Raza, J.D., Chief Counsel

No Significant Event

Back to Top